• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    B

    Botkin Hospital

    EST. 1910
    329论文总数
    1,580引用总数

    论文量&引用量时间轴

    机构学者

    论文(329)

    年份
    起
    –
    止
    排序
    1Suction-Assisted Miniaturized Percutaneous Nephrolithotomy Outcomes in Anomalous Kidneys: A Multicenter Prospective Study-An EAU-Endourology Collaboration.
    Vineet Gauhar,Ee Jean Lim, Bhaskar Kumar Somani,Jaisukh Kalathia, Edgar Beltrán-Suárez,Gadzhiev Nariman,Mahmoud Laymon,Kremena Petkova, Esteban Acuna,Mohamed Amine Lakmichi, Khi Yung Fong,Marek Zawadzki,

    BACKGROUND:Renal stones in anomalous kidneys pose surgical challenges due to altered anatomy. Miniaturized percutaneous nephrolithotomy (mini-PCNL) reduces morbidity, but concerns remain about stone-free rates (SFRs) and infection. Suction-assisted mini-PCNL (SM-PCNL) enhances fragment removal and controls intrarenal pressure, but its role in anomalous kidneys is unclear. OBJECTIVE:To evaluate perioperative outcomes of SM-PCNL in anomalous kidneys in a multicenter, real-world study and assess variations based on positioning, lithotripsy modality, and renal anomalies. METHODOLOGY:This prospective study across 15 centers (January-December 2024) included 287 adults undergoing SM-PCNL for renal stones in anomalous kidneys. Patients with normal anatomy, non-suction PCNL, or incomplete data were excluded. SFR was assessed via a 30-day non-contrast CT: 100% stone-free (Grade A), residual fragments ≤4 mm (Grade B), or >4 mm/multiple (Grade C, requiring reintervention). RESULTS:Malrotation (65.5%) was the most common anomaly, followed by duplex systems (25.1%), horseshoe kidneys (8.4%), and ectopic kidneys (1.0%). Median stone size was 1.7 cm. Supine positioning was used in 54.4%. Lithotripsy was performed with holmium laser (50.9%), thulium fiber laser (11.1%), or pneumatic lithotripsy (26.1%). Intraoperative clearance was 95.4%. At 30 days, 93.4% achieved Grade A, 5.6% Grade B, and 1.0% required reintervention. Complications were low; 0.7% had sepsis requiring intensive care unit admission. No transfusions or pleural injuries occurred. CONCLUSION:SM-PCNL using 18F suction sheaths with laser in a single stage achieved 93.4% complete SFR with negligible complications and minimal reintervention.

    2026Journal of endourology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2COPD and Kidney Disease: Not So Far Apart?
    Iuliana Stratan, Serghei Covantsev,Alexander G Mathioudakis,Alexandru Corlateanu

    This review synthesizes current literature on the epidemiology, mechanistic links, and clinical consequences of the COPD-CKD association. In addition to evaluating established risk factors such as age and tobacco smoking, we discuss emerging insights into the roles of novel biomarkers and epigenetic modifications in bridging the lung-kidney axis. The review further examines how the presence of CKD influences clinical management in COPD patients, including impacts on drug dosing, electrolyte balance, acid-base homeostasis, and outcomes during acute exacerbations, and conversely, how COPD can adversely affect renal function. Recognizing that the dual burden of COPD and CKD may worsen patient prognosis by increasing the risk for cardiovascular events, hospitalizations, and mortality, we advocate for early detection, routine screening using both creatinine and cystatin C measurements, and a multidisciplinary approach to care. Finally, we outline future research directions aimed at standardizing screening protocols, refining risk stratification, and developing targeted therapies that address shared pathogenic pathways.

    2026Respiratory medicine(2026)
    引用
    AI阅读
    加入学术空间
    3A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus
    Guilherme Fleury Perini, Ahmad Alhuraiji,Mary Ann Anderson, Gilberto Israel Barranco Lampón, Otavio Cesar Carvalho Guimarães Baiocchi,Ahmet Emre Eşkazan,Yeow Tee Goh,Wei-Han Huang,Mervat Mattar,Eugene Nikitin,Stephen Opat, Miguel A. Pavlovsky,

    The treatment landscape for Chronic Lymphocytic Leukemia has rapidly evolved from chemoimmunotherapy to highly effective targeted agents. Despite superior efficacy and safety profiles of these novel agents, challenges persist, particularly due to limited head-to-head trials and regional differences in drug availability and molecular testing. This multiregional expert consensus, developed by 13 hematology experts from Latin America, the Middle East and Africa, Asia-Pacific, and Russia using an adapted Delphi approach, provides evidence-informed recommendations for first-line treatment and sequencing tailored to patient risk and real-world resource constraints. The panel agreed on 16 key statements, emphasizing that targeted therapies are preferred for nearly all newly diagnosed patients. Molecular testing for del(17p), TP53 mutation, and IGHV status is recommended for prognosis and treatment planning. High-risk patients (del(17p) and/or TP53 mutation) should preferably receive continuous therapy with second-generation BTK inhibitors (acalabrutinib or zanubrutinib), which are generally preferred over ibrutinib due to safety advantages. Low-risk patients (IGHV-mutated, without del(17p)/TP53) are best suited for time-limited, venetoclax-based regimens. Upon relapse, switching therapeutic classes is recommended: venetoclax after continuous BTKi therapy, and BTKi after fixed-duration venetoclax. Overall, the consensus underscores the importance of individualized, shared decision-making that accounts for molecular risk, comorbidities, and patient preferences, while highlighting global disparities in access to modern CLL therapies.

    2026Blood Global Hematology(2026)
    引用
    AI阅读
    加入学术空间
    4Heart Failure and Chronic Kidney Disease in the Structure of Cardiovascular-Kidney-metabolic Syndrome: a Shift in Paradigm and Treatment Approaches
    S.R. Gilyarevsky, K.R. Akhmetova, M.V. Golschmidt, A.Yu. Shchedrina

    The paper is focused on a shift in approaches to treatment of heart failure (HF) and chronic kidney disease (CKD) as components of cardiovascularkidneymetabolic ( CKM) syndrome. It reviews evolution of concepts regarding the pathogenesis of heart failure with preserved ejection fraction (HFpEF) and, consequently, changing views on the role of reninangiotensin system activation in the development of this HF type. Current epidemiological data demonstrating a substantial increase in HFpEF prevalence are presented. The current classification of CKM syndrome which provides the basis for selecting background therapy at each stage of the syndrome, is described. The key role of abnormal adipose tissue in HFpEF development, as well as its important contribution to development and progression of CKD, is discussed. Significance of the bidirectional relationship between HF and CKD causing progression of both diseases is being discussed. A shift in approaches to background therapy for CKD and a place of irbesartan in the current management of patients with CKM syndrome and impaired kidney function are on the carpet. Data on the potential modification of treatment response in overweight and obese patients are presented. The findings of the I PRESERVE trial assessing irbesartan effects in patients with HFpEF, as well as the results of two pivotal irbesartan trials in patients with type 2 diabetes at high risk of CKD onset or progression, are discussed in a modern light. Data on the role of PPARγ activation in a beneficial effect of irbesartan on metabolic parameters, as well as its effects on uric acid levels in patients with hyperuricemia, are presented. KEYWORDS: cardiovascularkidneymetabolic syndrome, heart failure, chronic kidney disease, irbesartan. FOR CITATION: Gilyarevsky S.R., Akhmetova K.R., Golschmidt M.V., Shchedrina A.Yu. Heart failure and chronic kidney disease in the structure of cardiovascular-kidney-metabolic syndrome: a shift in paradigm and treatment approaches. Russian Medical Inquiry. 2026;10(9):621–628 (in Russ.). DOI: 10.32364/2587-6821-2026-10-9-5

    2026Russian Medical Inquiry(2026)
    引用
    AI阅读
    加入学术空间
    5Should Aspirin Be Discontinued in Patients Taking It for Primary Cardiovascular Prevention?
    Vadim Zakiev,Anna Gvozdeva, Oxana Ushakova
    2026Journal of the American Geriatrics Society(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 329 篇论文

    合作机构(99)

    Russian Medical Academy of Continuous Professional Education,Ministry of Health合作论文 53
    Sechenov University合作论文 15
    Pirogov Russian National Research Medical University,Ministry of Health合作论文 8
    俄罗斯科学院合作论文 7
    俄罗斯联邦卫生部合作论文 7
    Moscow Clinical Scientific Center合作论文 7
    圣彼得堡大学合作论文 6
    City Clinical Hospital合作论文 6
    莫斯科罗蒙诺索夫国立大学合作论文 6
    俄罗斯人民友谊大学合作论文 6

    机构统计